LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

Home・Aktien・Envista Holdings Corp

Envista Holdings Corp

Open

BrancheGesundheitswesen

22.85 1.02

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.58

Max

23.09

Schlüsselkennzahlen
By Trading Economics
Einkommen	5.8M 39M
Verkäufe	-45M 706M
KGV Branchendurchschnitt	57.439 49.888
EPS	0.36
Gewinnspanne	5.485
Angestellte	12,000
EBITDA	-42M 63M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+28.55% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-374M 3.8B
Vorheriger Eröffnungskurs	21.83
Vorheriger Schlusskurs	22.85

Nachrichtenstimmung

By Acuity

72%

28%

303 / 344 Ranking in Healthcare

Envista Holdings Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Envista Holdings Corp Prognose

Kursziel

By TipRanks

28.55% Vorteil

12-Monats-Prognose

Durchschnitt 29.4 USD 28.55%

Hoch 34 USD

Tief 21 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Envista Holdings Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Envista Holdings Corp – Dist abgegeben haben.

Stimmung

By Acuity

303 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Envista Holdings Corp

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.